IP Library Granted Patent US 8,263,139
Granted Patent B2
US 8,263,139 · App. 11/501,393 · Granted Sep 11, 2012

Protein kinase modulation by hops and

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,139
App. No.
11/501,393
Granted
Sep 11, 2012
Kind
B2
Abstract

Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.

Claims (5)

1. A method of reducing serum glucose level in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a composition comprising about 5:1 ratio of reduced-isoalpha acids to Acacia extract.

2. The method of claim 1 , wherein the reduced isoalpha acid is selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, hexahydro-isoadhumulone, and rho-isoalpha acids.

3. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbents, detergents, and emulsifying agents.

4. The method of claim 1 , wherein the composition further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.

5. The method of claim 1 , wherein the composition further comprises an antidiabetic drug selected from the group consisting of rosiglitazone, troglitazone, pioglitazone, and metformin.

Assignments (8)
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 057981/0156 Recorded Dec 24, 2025
From: FORTRESS CREDIT CORP.
To: METAGENICS LLC (FKA METAGENICS, INC.); METAPROTEOMICS, LLC
Reel/Frame 074057/0392 →
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 058015/0602 Recorded Dec 23, 2025
From: FORTRESS CREDIT CORP.
To: METAGENICS LLC (FKA METAGENICS, INC.); METAPROTEOMICS, LLC
Reel/Frame 074050/0670 →
SECURITY INTEREST Recorded Dec 22, 2025
From: METAGENICS LLC
To: WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT
Reel/Frame 073293/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: METAPROTEOMICS, LLC
To: METAGENICS LLC
Reel/Frame 066485/0677 →
SECURITY INTEREST Recorded Nov 4, 2021
From: METAGENICS, INC.; METAPROTEOMICS, LLC
To: FORTRESS CREDIT CORP. (AS COLLATERAL AGENT)
Reel/Frame 058015/0602 →
SECURITY INTEREST Recorded Nov 1, 2021
From: METAGENICS, INC.; METAPROTEOMICS, LLC
To: FORTRESS CREDIT CORP., AS COLLATERAL AGENT
Reel/Frame 057981/0156 →
RELEASE OF SECURITY INTEREST Recorded Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →
SECURITY AGREEMENT Recorded Oct 15, 2009
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 023373/0684 →